Alpheus Medical

Alpheus Medical is pioneering a drug-ultrasound combination therapy designed to treat aggressive brain cancers like glioblastoma without invasive surgery. Their investigational approach leverages an FDA-approved tumor-targeting drug, which is activated non-invasively by a proprietary ultrasound system to create localized reactive oxygen species and stimulate an immune response. The company is advancing this therapy through a 505(b)(2) regulatory pathway and is currently enrolling patients in a pivotal Phase 2b trial, supported by early clinical data showing a favorable safety profile and encouraging biological activity.

A proprietary platform combining a tumor-accumulating drug with a low-intensity, diffuse ultrasound system to achieve localized pharmacologic activation inside solid tumors, triggering tumor cell death and an immune response.

Total raised: $62M

Alpheus competes in the glioblastoma space against next-gen chemotherapies, immunotherapies, and device-based therapies like Novocure's Tumor Treating Fields. Its main differentiation is the non-invasive, outpatient, and repeatable nature of its drug-ultrasound combination, which aims to offer localized potency with potential systemic immune benefits without surgery.